There have been very few new therapies in the critical care arena over the past half a century. Ikaria is committed to changing that.
We use our scientific expertise to develop biotherapeutic solutions for the critical care market. Our research continues to break new ground toward our goal of improving the clinical outcomes for critically ill patients. INOMAX® (nitric oxide) for inhalation is our first commercialized product and demonstrates our ability to develop therapies that meet the significant unmet needs of these patients. But it’s only just the start (see Current R&D).